Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned new fundraising through debt or equity during the call. The company has already repaid the INR 34 crores term loan from IPO proceeds; only working capital loans remain (~INR 190 crores). Interest costs are expected to reduce as collections improve and credit facilities are reduced by March. Capex of INR 14 crores raised in the IPO is being utilized gradually, with full-scale deployment starting in Q3 and commissioning expected by the fiscal year-end. The company plans to fund growth and capacity expansions through operational cash flows and rem

Any current/future capex/capital investment/strategic investment?

The Barwasni capacity enhancement and the new Dry Flowable (DF) facility are firmly on track. Of the INR 14 crores raised for capex in the IPO, utilization in Q2 was minimal, focusing instead on seasonal sales. Full-scale deployment of capex will begin in Q3 FY26. The completion of these projects is expected over the next two quarters, with commissioning starting by the end of the fiscal year. Strategic priorities include the Barwasni expansion and the dry flowable plant within the guided timeframe. The company also plans to deepen backward integration to enhance resilience and maintain tight

Future growth expectations in sales/revenue/volumes?

Indogulf expects continued growth driven by better water availability and favorable agronomic conditions, especially in H2 FY26. Focus on launching 2-3 new products in Abhiprakash and 4-5 new products overall next year, expanding their product portfolio. Brand business including Abhiprakash projected to be a key growth driver, having already contributed 9% to revenue. Anticipates improving Q1 performance by focusing more on B2B business and strategizing for higher EBITDA and PAT. Expect gradual increase in biologicals and plant nutrients share to 15-20% of revenue in next 2-3 years due to focu

Future growth expectations in earnings/operating earnings/profits/EPS?

Company expects promising growth in Q3 and Q4 FY26, driven by better rainfall and Rabi season crop prospects. EBITDA margin anticipated to improve beyond Q2 levels (above 10%), supported by operational efficiency. Biologicals and plant nutrients segment projected to grow in absolute and percentage terms, becoming a key focus area. Over next 2-3 years, biologicals and nutrients may contribute approximately 15-20% of revenue. Launching 2-3 new products annually in subsidiary Abhiprakash to drive volume growth. Strategic focus on deepening market penetration, increasing multi-brand presence, and

Indogulf Cropsciences LtdQ2 FY26Fertilizers & Agrochemicals

Indogulf Cropsciences Ltd Q2 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹61.04P/E: 11.0Market Cap: ₹423 CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Indogulf expects continued growth driven by better water availability and favorable agronomic conditions, especially in H2 FY26.
Focus on launching 2-3 new products in Abhiprakash and 4-5 new products overall next year, expanding their product portfolio.
Brand business including Abhiprakash projected to be a key growth driver, having already contributed 9% to revenue.
Anticipates improving Q1 performance by focusing more on B2B business and strategizing for higher EBITDA and PAT.
Expect gradual increase in biologicals and plant nutrients share to 15-20% of revenue in next 2-3 years due to focused marketing and schemes.
Plans to deepen market penetration and expand multi-brand presence.
Revenue growth for FY26 may be below earlier 30-35% guidance due to erratic monsoon but still expects overall positive growth.
Optimistic about export market development, especially in biologicals to Europe over time.

Margin guidance

Category 2

Company expects promising growth in Q3 and Q4 FY26, driven by better rainfall and Rabi season crop prospects.
EBITDA margin anticipated to improve beyond Q2 levels (above 10%), supported by operational efficiency.
Biologicals and plant nutrients segment projected to grow in absolute and percentage terms, becoming a key focus area.
Over next 2-3 years, biologicals and nutrients may contribute approximately 15-20% of revenue.
Launching 2-3 new products annually in subsidiary Abhiprakash to drive volume growth.
Strategic focus on deepening market penetration, increasing multi-brand presence, and expanding B2B and B2C segments.
Working capital discipline and backward integration to support margin sustainability.
Management refrains from giving strict numerical guidance but remains optimistic about outperforming industry peers and continuing overall revenue and profit growth.

See what Indogulf Cropsciences Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or planned new fundraising through debt or equity during the call.
The company has already repaid the INR 34 crores term loan from IPO proceeds; only working capital loans remain (~INR 190 crores).
Interest costs are expected to reduce as collections improve and credit facilities are reduced by March.
Capex of INR 14 crores raised in the IPO is being utilized gradually, with full-scale deployment starting in Q3 and commissioning expected by the fiscal year-end.
The company plans to fund growth and capacity expansions through operational cash flows and remaining IPO proceeds rather than raising additional equity or debt as per current discussion.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders. However, from the discussion, the following related insights can be gleaned: - No specific commentary on order book size or pending orders was provided during the Q2 FY26 earnings call. - The company highlighted growth in product launches with 12 new products launched in H1 FY26. - There is an expectation of adding 2-3 new products in Abhiprakash (subsidiary) in the coming years. - The management anticipates improved demand in H2 FY26 due to better water availability and favorable agronomic conditions. - Export registrations for 1-2 products are expected in Q3 or Q4. - The company is focusing on strengthening product pipeline, market penetration, and deepening dealer presence. For precise order book figures, separate official company disclosures or quarterly reports would be required.

See what Indogulf Cropsciences Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The Barwasni capacity enhancement and the new Dry Flowable (DF) facility are firmly on track.
Of the INR 14 crores raised for capex in the IPO, utilization in Q2 was minimal, focusing instead on seasonal sales.
Full-scale deployment of capex will begin in Q3 FY26.
The completion of these projects is expected over the next two quarters, with commissioning starting by the end of the fiscal year.
Strategic priorities include the Barwasni expansion and the dry flowable plant within the guided timeframe.
The company also plans to deepen backward integration to enhance resilience and maintain tight working capital discipline and channel hygiene.

Track Indogulf Cropsciences Ltd — get its next earnings analysis in your feed

How does Indogulf Cropsciences Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

ThisIndogulf Cropsciences Ltd

Rev 3Mar 2

See where Indogulf Cropsciences Ltd sits in Fertilizers & AgrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Indogulf Cropsciences Ltd rank in Fertilizers & Agrochemicals?

Compare Indogulf Cropsciences Ltd against every Fertilizers & Agrochemicals company (Q2 FY26) on revenue, margins and earnings-call signals.

View Fertilizers & Agrochemicals leaderboard →

What Indogulf Cropsciences Ltd's management said in earlier quarters

Others in Fertilizers & Agrochemicals this season

Bhagiradha Chemicals & Industries Ltd (Q2 FY26)
140.1 crore, up 35% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q2 FY26 investor presentation — and how it ran
Bhagiradha Chemicals & Industries Ltd (Q3 FY26)
114.0 crore, up 11% YoY from Rs. Key investor presentation takeaways from Bhagiradha Chemicals & Industries Ltd's Q3 FY26 investor presentation — and how it ran
Advance Agrolife Ltd (Q3 FY26)
Q3 FY26 revenue from operations was ₹1,338 million, up 18% year-on-year (YoY) from ₹1,134 million in Q3 FY25 (Pages 23-24). Key investor presentation takeaways
Dhansa Labs Ltd (Q4 FY26)
120-140 crores in additional annual revenue upon stabilization, with initial revenue of around Rs. Key concall takeaways from Dhansa Labs's Q4 FY26 earnings…

Compare:vs Coromandel International Ltd vs Fertilizers & Chemicals Travancore Ltd vs Sumitomo Chemical India Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →